Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections -- Qualified Infectious ...

Lead clinical candidate CTX-187 is a novel antimicrobial immunotherapy developed to treat clinically-prevalent and multi-drug resistant Gram-negative bacterial infections Qualified Infectious Disease ...

Drugmakers must focus on developing new antibiotics to fight hospital “superbugs” including meningitis and other infections that can resist last-line treatments, the World Health Organization (WHO) ...

WHO releases new target product profiles for urgently needed antibiotics: Geneva Thursday, March 12, 2026, 09:00 Hrs [IST] The World Health Organization (WHO) published three new ...

There are four classes of anti-infectives used for BRD treatment. It is impotant to use the correct class of antibiotic to ...

We need a reliable pipeline with new antibacterial agents that are innovative, affordable, accessible to all those who need ...

Researchers report that photodynamic therapy increases antibiotic penetration and disrupts resistance mechanisms in laboratory strains.

BRD is often framed as stress, viruses and bacteria. Managing inflammation tied to endotoxin helps explain why some cattle recover faster than others ...

Findings support Solenic’s SOLA-2 non-invasive platform for advanced infection care by enhancing antibiotic effectiveness ...

BV100 Phase 1, single- and multiple-ascending dose clinical trial data include pharmacokinetics, safety and tolerability data. BV100 demonstrated a dose-proportional pharmacokinetic profile and was ...

Penn State College of Medicine is reporting on two cases of destructive infant meningitis linked to Paenibacillus infection, documenting severe neurologic injury and raising concerns about diagnosis ...